Article · 31 Jul 2024
Review articlePublished 20 Mar 2018
Monoclonal Antibodies Handling and Administration Risk Management
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
ABSTRACT Background The use of Monoclonal Antibodies (MABs) has provided a new approach to treat various diseases and is in constant evolution. Hospital at home, new regulations and technologies are the next challenges for which healthcare professionals are confronted with. Therefore, risk assessment of MAB handling and administration must be considered. The aim of this study was to develop a tool providing recommendations regarding the MAB handling and administration. Method A review of the scientific literature was undertaken to identify MABs hazard characteristics, their immunogenic potential and their complexity of preparation. A tool was developed to classify MABs requiring a preparation in different groups providing specific handling and administration recommendations. Results An evaluation algorithm was developed to classify MABs regarding their toxicity and complexity of preparation. 28 MABs and 2 fusion proteins were assessed: 6 MABs presented a carcinogenic and/or mutagenic potential in animals. More than 65% of the MABs assessed exhibited teratogenic potential and 25% were highly or moderately immunogenic. 3 groups were defined providing specific recommendations for working staff. MAB side effects were also listed highlighting particular precautions for administration. Conclusion Most of the MABs assessed were not listed in known hazard drug lists (NIOSH, IARC). However, the literature reviewed has highlighted that some MABs exhibit carcinogenic or mutagenic properties in animal studies. Many of them are toxic for reproduction. Furthermore, sensitizing reaction and serious side effects can be observed. Despite their high molecular weight, MABs inhalation (ability to generate aerosol or powder handling) has been described as a potential route of occupational exposure. Studies on humans at low dose exposure should be conducted to allow the establishment of clear safety guidance for MABs handling and administration.
Keywords
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in International Journal of Pharmacy.
Article · 31 Jul 2024
Bridging Genetics and Pharmacology for Personalized Treatment through Pharmacogenomics
Article · 31 Jul 2024
The Impact of Pharmacotherapy on Well-Being of Modern Health Care
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalInternational Journal of Pharmacy
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Jaadar Y”
- BylineArticles whose byline prints “Maes B”
- BylineArticles whose byline prints “Vidts LA”
- BylineArticles whose byline prints “Liévin V”
- BylineArticles whose byline prints “Demoulin M”